Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alfred Huang

Family Medicine Irving, TX Medical Doctor

NPI 1083689194 CMS profile 276155

117 N MacArthur Blvd, Irving, Irving, TX 75061

Open in the dashboard

General payments

$8,762

472 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alfred Huang of Irving, TX is reported in the CMS Open Payments database as having received $8,762 across 472 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $480 26
2024 General $587 32
2023 General $609 31
2022 General $922 50
2021 General $2,551 130
2020 General $2,236 122
2019 General $1,377 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alfred Huang
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Alfred Huang were reported at $480. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Alfred Huang Family Medicine median Middle half National median
2019 $1,377 $150 $41–$543 $163
2020 $2,236 $120 $32–$415 $114
2021 $2,551 $137 $35–$551 $132
2022 $922 $137 $37–$512 $149
2023 $609 $149 $42–$545 $160
2024 $587 $156 $44–$560 $164
2025 $480 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amarin Pharma Inc. $2,410 122 payments
  2. AstraZeneca Pharmaceuticals LP $1,231 66 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,085 48 payments
  4. Novo Nordisk Inc $768 50 payments
  5. Sanofi-Aventis U.S. LLC $579 30 payments
  6. Lilly USA, LLC $456 27 payments
  7. AbbVie, Inc. $256 15 payments
  8. Janssen Pharmaceuticals, Inc $233 16 payments
  9. Pfizer Inc. $232 8 payments
  10. Kowa Pharmaceuticals America, Inc. $199 13 payments
  11. Other $1,313 77 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,725 470 payments
  2. Education $37 2 payments
Products named General payments · program years 2019–2025
  1. Vascepa Cardiovascular $1,914 91 payments
  2. JARDIANCE $954 42 payments
  3. FARXIGA $704 38 payments
  4. Ozempic $575 38 payments
  5. Vascepa Hypertriglyceridemia $496 31 payments
  6. TRADJENTA $410 18 payments
  7. RYBELSUS $396 24 payments
  8. GLYXAMBI $392 17 payments
  9. BREZTRI $377 20 payments
  10. SYNJARDY $362 16 payments
  11. Other $5,984 329 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

56

Median for Family Practice: 1,826

Drug cost

$483

Median for Family Practice: $120,094

Branded share of claims

0%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Losartan Potassium Generic 11 $216
Atorvastatin Calcium Generic 20 $163
Alprazolam Generic 13 $74
Clonazepam Generic 12 $30

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $131
$131 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $107
$107 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $91
$91 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $73
$73 — —
VRAYLAR
  • AbbVie, Inc. $52
$52 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

472 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record